Gedeon Richter has announced positive topline results from Phase I and Phase III clinical studies for its proposed biosimilar to RoActemra® tocilizumab that has the development code 'RGB-19'. The Hungarian pharmaceutical firm points out in a statement on the webiste of the Budapest Stock Exchange that Phase I clinical study evaluated the equivalence of pharmacokinetics […]